Literature DB >> 11882358

Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications.

Yu-Tzu Tai1, Klaus Podar, Stine-Kathrein Kraeft, Fengfei Wang, Gloria Young, Boris Lin, Deepak Gupta, Lan Bo Chen, Kenneth C Anderson.   

Abstract

OBJECTIVE: Since the central hallmarks of human multiple myeloma (MM) are abnormalities in immunoglobulin (Ig) gene rearrangement, IgH class switching, and DNA damage repair, and since Ku86 and Ku70 proteins are central to these processes, aberrant Ku function may play a role in MM pathogenesis. Our prior studies demonstrated a 69-kDa Ku86 variant in freshly isolated patient MM cells that confers sensitivity to DNA damage. We also showed that Ku86 on the cell surface of CD40-activated MM cells mediates homotypic tumor cell adhesion, as well as heterotypic adhesion to bone marrow stromal cells. We here define the mechanism and functional significance of CD40-induced Ku translocation from the cytoplasm to the cell membrane in MM cells vs normal B cells.
MATERIALS AND METHODS: We examined Ku86 and Ku70 translocation following CD40 activation in human MM cells vs normal tonsillar B lymphocytes. We then identified the functional sequelae of membrane Ku86 and Ku70 expression on CD40-activated human MM cells.
RESULTS: CD40 activation induces translocation of both Ku86 and Ku70 to the cell surface of MM cells, but not normal tonsillar B cells. Moreover, CD40 activation triggers Ku association with CD40 only in CD40-activated MM cells. Finally, CD40-activated MM cells adhere to fibronectin and are protected against apoptosis triggered by irradiation or doxorubicin; conversely, antibodies to Ku both inhibit tumor cell binding and restore sensitivity to these agents.
CONCLUSION: These results demonstrate functional significance of Ku translocation to the cell membrane of CD40-activated human MM cells. Therefore, targeting Ku86 and Ku70, with blocking peptides for example, might serve as a novel treatment strategy in human MM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882358     DOI: 10.1016/s0301-472x(01)00786-x

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

Review 2.  Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Authors:  Arun Balakumaran; Pamela Gehron Robey; Neal Fedarko; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

3.  β-Carotene-induced apoptosis is mediated with loss of Ku proteins in gastric cancer AGS cells.

Authors:  Yoona Park; Jiyeon Choi; Joo Weon Lim; Hyeyoung Kim
Journal:  Genes Nutr       Date:  2015-05-16       Impact factor: 5.523

4.  Bovine Pancreatic RNase A: An Insight into the Mechanism of Antitumor Activity In Vitro and In Vivo.

Authors:  Islam Saber Ead Mohamed; Aleksandra V Sen'kova; Oleg V Markov; Andrey V Markov; Innokenty A Savin; Marina A Zenkova; Nadezhda L Mironova
Journal:  Pharmaceutics       Date:  2022-05-30       Impact factor: 6.525

5.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Authors:  Yu-Tzu Tai; Myles Dillon; Weihua Song; Merav Leiba; Xian-Feng Li; Peter Burger; Alfred I Lee; Klaus Podar; Teru Hideshima; Audie G Rice; Anne van Abbema; Lynne Jesaitis; Ingrid Caras; Debbie Law; Edie Weller; Wanling Xie; Paul Richardson; Nikhil C Munshi; Claire Mathiot; Hervé Avet-Loiseau; Daniel E H Afar; Kenneth C Anderson
Journal:  Blood       Date:  2007-09-28       Impact factor: 22.113

6.  Interaction of Rickettsia felis with histone H2B facilitates the infection of a tick cell line.

Authors:  Chutima Thepparit; Apichai Bourchookarn; Natthida Petchampai; Steven A Barker; Kevin R Macaluso
Journal:  Microbiology (Reading)       Date:  2010-06-17       Impact factor: 2.777

7.  Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type.

Authors:  Bernard Krust; Diala El Khoury; Isabelle Nondier; Calaiselvy Soundaramourty; Ara G Hovanessian
Journal:  BMC Cancer       Date:  2011-08-03       Impact factor: 4.430

8.  Ku86 exists as both a full-length and a protease-sensitive natural variant in multiple myeloma cells.

Authors:  Charles A Gullo; Feng Ge; Geraline Cow; Gerrard Teoh
Journal:  Cancer Cell Int       Date:  2008-04-29       Impact factor: 5.722

Review 9.  Apoptosis and molecular targeting therapy in cancer.

Authors:  Mohamed Hassan; Hidemichi Watari; Ali AbuAlmaaty; Yusuke Ohba; Noriaki Sakuragi
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

10.  A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.

Authors:  Lijie Xing; Liang Lin; Tengteng Yu; Yuyin Li; Shih-Feng Cho; Jiye Liu; Kenneth Wen; Phillip A Hsieh; Krista Kinneer; Nikhil Munshi; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Leukemia       Date:  2020-02-14       Impact factor: 11.528

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.